stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) Revenue
Amylyx Pharmaceuticals, Inc.'s revenue for fiscal 2024 was $87.4M, down 77.1% from $380.8M in fiscal 2023. Over the past ten years it has ranged from $285.0K (fiscal 2021) to $380.8M (fiscal 2023); the current reading is higher than 80% of that period. Amylyx Pharmaceuticals, Inc. ranks 48th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2024 | $87.4M | (77.06%) |
| FY2023 | $380.8M | 1,612.94% |
| FY2022 | $22.2M | 7,700.00% |
| FY2021 | $285.0K | (56.15%) |
| FY2020 | $650.0K | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Dec 2024 | −$665.0K | — |
| Sep 2024 | $416.0K | — |
| Jun 2024 | −$1.0M | — |
| Mar 2024 | $88.6M | (18.26%) |
| 7 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| PRGO Perrigo Company plc compare | $4.1B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| TRLV Trulieve Cannabis Corp. compare | $1.1B |
| LQDA Liquidia Corporation compare | $450.9M |
| AMLX Amylyx Pharmaceuticals, Inc. | $87.4M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on AMLX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement